ER Positive Breast Cancer Clinical Trials in Boston, Massachusetts
3 recruitingBoston, Massachusetts
Showing 1–3 of 3 trials
Recruiting
Phase 3
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
Breast CancerMetastatic Breast CancerHER2-Negative Breast Carcinoma+2 more
Olema Pharmaceuticals, Inc.510 enrolled233 locationsNCT06016738
Recruiting
Phase 1
Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer
Breast CancerMetastatic Breast CancerHER2-negative Breast Cancer+2 more
Olema Pharmaceuticals, Inc.190 enrolled16 locationsNCT05508906
Recruiting
Phase 2
DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
Breast CancerBreast Cancer FemaleHER2-Negative Breast Carcinoma+4 more
Sarah Sammons, MD58 enrolled3 locationsNCT06176261